Najnowsze Wpisy

FDA report details poor quality control, undisclosed THC in many CBD products –

In a report released to the US House and Senate Committees on Appropriations, FDA Commissioner Dr Stephen Hahn, MD, detailed what the agency has found in testing CBD/hemp products from 2014 to the present. The report paints a picture of uneven quality, with many products having less than 80% of the stated amount of CBD or in some cases more than 120% of the amount on the label.  Only those products that claimed an amount of CBD on the label were evaluated in this way.

THC found in many products

More worrying to observers was the fact that many of the products contain THC.  In one case, a product that was tested before 2018 contained so much THC that it was referred to the Drug Enforcement Agency, the report said.

THC, or tetrahydrocannabinol, is the narcotic fraction of the Cannabis sativa​ plant.  Varieties of this plant used in the CBD/hemp products trade are supposed to have less than 0.3% THC by dry weight in order to qualify as ‘industrial hemp’ in a regulatory sense.  Amounts of THC above that level put a product into the schedule one category of controlled substances and move them into the bailiwick of DEA. 

The report stated that in all FDA had tested 112 CBD/hemp products through the end of 2018. In a table in the report summarizing those results, FDA found that of the 78 products tested that were marketed as CBD products, 46 contained THC at some level.  In addition, 11 of the products contained no detectable levels of CBD.  FDA found that in 2014 of the 23 products tested, only 35% met label claim for CBD content. The report did not give further detail on how the other 55 products tested in the 2015-2018 period performed on the CBD content vs label claim front.

Problems persist in 2019 and 2020 testing 

In 2019 FDA tested 34 products. FDA selected products to test based on those that were making disease treatment claims and those that had been marketed toward vulnerable populations.  FDA stepped up the testing in 2020, analyzing another 147 products to date. The results seemed to indicate the industry has made little progress on the quality control front over the years. 

In 2019 FDA tested 16 tinctures or oils, seven edibles, one capsule/powder product, four beverages and three products meant for pets.  Of the 10 oil products that made a CBD claim on the label, only 4, or 40%, came within 20% over or under of that amount.  In addition, 11 of those products contained THC, even though it was not disclosed on the labels. None of the edible products or beverages that were making a CBD contain claim on the label fell within the ±20% window.

The 2020 testing results were even less reassuring from a quality control perspective. Of the 147 products tested, nine contained no CBD, 18 products (or 18%) were understrength, with less than 80% of CBD amount, 46 products (15%) fell with the ±20% window, and 38 products (37%) and more than 120% of the state CBD amounts.  In addition, 72 producst (49%) contained THC above the limit of quantification. 

Plan in place to test statistically representative sample of what’s on market

Going forward Hahn said the Agency is developing a plan to test a representative selection of products that will give a more comprehensive view of the marketplace.  To determine how to go about this the Agency has purchased data on brands, product categories, and distribution channels for CBD products. And FDA is developing its own lists of CBD brands via Internet searches and data analytics.

“These preliminary data are from a limited sample size and cannot be used to draw conclusions about the marketplace and supports the need for the long-term study, which will capture multiple retail sources (on-line and brick and mortar) and a greater number of products,”​ the report stated.
The results from the planned sampling study will help the Agency gain insight into the characteristics of representative products in the current CBD marketplace,” ​it added.

NPA: THC presence could threaten vulnerable populations

While the report might have put to rest some fears about widespread heavy metal, pesticide or synthetic cannabinoid adulteration in these products, it’s far from reassuring, said Daniel Fabricant, PhD, president and CEO of the Natural Products Association.

“The THC thing should be cause for alarm,”​ Fabricant told NutraIngredients-USA. “Were any of these products labeled for use by children?  I think FDA should release the names of these companies and take action against them.”

Fabricant said from NPA’s point of view the results are indicative of an industry that is not well educated on GMP compliance.

“It has been such a gold rush mentality.  You have a lot of people who might know hemp farming but they don’t know the GMP regulations,”​ he said.

Fabricant said beyond the presence of THC, the inconsistent levels of CBD could be a concern, too.

“FDA needs to set a safe level on CBD.  How much is too much? For these products that had more than 120% of label claim, are there adverse events associated with that?” ​Fabricant said.

Industry runs risk of letting rogue players write the story

Steve Hoffman, principal in the firm Compass Natural Marketing, has been involved in the CBD/hemp marketplace from the beginning, having worked on some of the state ballot initiatives that first opened the door to the trade.  Hoffman said the report lays out the risk the industry runs by not banding together to present a unified front advocating for quality.

“I encourage manufacturers of hemp-CBD related products to tune in to regulations governing the dietary supplements industry and to become members of AHPA, NPA and others that promote the highest quality GMPs and regulatory compliance. Also, it is preferable for the industry to encourage standards than to have the FDA’s decision making on hemp CBD be dictated by a few wild west players,”​ Hoffman said.

Does the 0.3% THC level make sense?

On the THC front, Hoffman said there continues to be disagreement about whether the federal 0.3% limit, which some allege was determined arbitrarily, still makes sense.  Nevertheless, the inconsistent levels still speak to ragged quality within the industry.

“Regarding the question of THC, that is particular, and problematic, and the industry should do better. However, Vote Hemp this week issued a petition asking Congress to change the definition of hemp to allow for 1% THC instead of the current, arbitrarily set 0.3%. This will help many farmers and manufacturers stay in business, and 1% THC is still hemp and NOT marijuana,” ​Hoffman added.

THC and the psychoactive effect ‚high’ – Nation Valley News

Cannabis 101: CBD vs THC

A column by Dr. Pierre Milot, PhD.

In a previous article, I talked about the cannabinoid CBD, what it is and what it can do.
Now, in this article, I’m going to describe the other most important cannabinoid contained in cannabis.  As I said before, there are hundreds of cannabinoids, but CBD and THC are the most prevalent and the most useful as far as medicine is concerned.  But the reason why cannabis (or marijuana, as it used to be called), was so popular over the years is for its THC content and the ability to get people “high’ or ‘stoned’.

What is THC?

THC is the most common and well-known cannabinoid found in the cannabis plant.  Often associated with psychoactive properties, THC, aside from its use for recreational activities, can be very helpful in different medicinal applications.  THC’s pain-relieving properties make it effective for patients managing their chronic pain.

What heath conditions can cannabis help?

Besides chronic pain, THC can also:

Ease stomach discomfort through the reduction of nausea and vomiting;
Stimulate appetite in older patients and those experiencing chemotherapy for cancer treatment;
Help those who suffer from chronic stomach issues such as Crohn’s disease and irritable bowel syndrome;
Help reduce muscle spasm and control excessive muscle movements, thus helping patients with conditions such as Parkinson’s disease.

What role do other marijuana cannabinoids play?

Cannabis is much more effective as a whole plant as opposed to when one cannabinoid is used in isolation.  It’s the interactions taking place among the various cannabinoids called ‘entourage effect’ that helps drive positive effects in the human body.

THC and CBD work in harmony on the endocannabinoid system inside the body.  For example, having a balance of THC and CBD in a strain (we call them ‘chemovar’ now) of cannabis can allow for the highly successful pain-relieving aspects of THC with less of the psychoactive effect, because the non-psychoactive CBD counteracts the psychoactive effect of THC.  In fact, taking a full dropper of 15 to 25 mg of CBD will reduce in half an unwanted ‘high’ due to an accidental intake of THC.

Though THC ad CBD are the most prominent compounds, other main cannabinoids such as tetrahydrocannabinolic acid (THCA), canabichromene (CBC), CBG, CBN can provide a range of multiple benefits.  We are finding out more and more about these other cannabinoids as research progresses.  For example, recent studies have found THCS to have anti-inflammatory, neuroprotective, anti-emetic (anti vomiting) and antiproliferative properties (retard the spread of malignant cells into surrounding tissues), while CBC appears to be an effective antimicrobial, anti-viral, anti-depressant and analgesic compound.

What are cannabis terpenes and how can they help?

Terpenes are compounds in the cannabis plant that lend the different plant chemovars their fragrance and flavor and also have medicinal properties.  They number well over 100 and interact perfectly with the endocannabinoid (ECS).  They work in synergy (increase the effect of CBD) with cannabinoids in a range of activities from promoting sleep to elevating mood and providing stress relief.

In my next article, I will expand a bit more on the genetics of Cannabis, THC content and cultivation of cannabis.

Once again, I encourage you to email me any questions you might have on cannabis, request more explanations or share a success story with other readers at:

Talk to you soon

Dr. Pierre Milot, PhD., is a Certified Medical Cannabis Counsellor
 and resident of Winchester, Ontario.

Scroll down to share this article. Scroll down to search Scroll down to comment.

FDA study finds some CBD products are mislabeled – Food Dive

Dive Brief:

  • In a report to the U.S. House Committee on Appropriations and the U.S. Senate Committee on Appropriations, the FDA released findings from its sampling study on the current CBD marketplace and determined that many of the products tested were mislabeled, containing either less or more CBD than advertised.
  • Two hundred products were randomly chosen for testing this year, including tinctures, oils, capsules, edibles, drinks and pet products. Testing for cannabinoids was done for 147 of the 200 products and found that 49% contained some THC. Out of the 102 products that listed a specific amount of CBD, 18% of products contained significantly less than the amount indicated and 37% contained significantly more than indicated. 
  • For the 20 edible and beverage products tested that had an amount of CBD marketed on their labels, five had less than 80% of the amount of CBD indicated and six had more than 120% of the CBD marketed on its label. 

Dive Insight:

As CBD remains in a gray area, these studies could bring the FDA a step closer to federal regulation. ​The agency said in the report that further understanding the CBD products on the market right now is „critical to making informed decisions about how best to protect public health in the current marketplace.” 

This report comes as the FDA’s fiscal year 2021 spending bill is currently in markup and appropriators have said that some of the funding will be put toward a potential framework for regulating CBD, Politico reported. In order to continue its larger testing plans on CBD products, a funding boost could help. The agency said these preliminary study results are from a limited sample size and supports the need for a bigger and longer-term study, which will look at products both online and in brick-and-mortar outlets.

Betsy Booren, senior vice president of regulatory and technical affairs at the Consumer Brands Association, said in a statement that this FDA report on labeling accuracy further emphasizes the need for federal regulatory clarity. 

„Allowing bad actors to continue to put products on the market, unchecked, is a threat to consumer safety everywhere,” she said. „The consumer packaged goods (CPG) industry applauds FDA’s efforts and urges Congress to provide more funding and resources to FDA to move quickly through this process.”

It has been more than a year since the FDA’s first public hearing on CBD, where manufacturers expressed confusion about regulation and pushed for clarity. In the new report, the FDA said that its public hearing last year and its open docket provided useful information and raised concerns about the quality and content of CBD products on the market. But FDA said testing has been limited in scope and has not yet provided a broader understanding of the market, which is why they are now pushing for further testing.

The 2018 Farm Bill no longer classified hemp and its derivatives as controlled substances, so the crop can be grown and distributed in most states, but under the federal Food, Drug and Cosmetic Act, it is still illegal to add CBD to food. However, states have passed their own laws and ​CBD continues to be added to a variety of products, including beer, snacks, coffee, cocktails and jelly beans. Lawmakers have expressed wanting the FDA to move faster on regulation than the several years anticipated because the crop’s production has the potential to boost agricultural revenue. 

Last year, the agency released an update about CBD, saying that it couldn’t give the ingredient generally recognized as safe status or approve products that contain it. FDA has continued to issue warning letters to companies wrongly using or advertising CBD and more could be coming as its testing continues. 

Cannabis Strategic Ventures Announces Record Month with $1.3M in June Cannabis Sales – GlobeNewswire

LOS ANGELES, July 09, 2020 (GLOBE NEWSWIRE) — via NetworkWire — Cannabis Strategic Ventures (OTCQB:NUGS) (“NUGS” or the “Company”), an emerging leader in the U.S. cannabis marketplace, is excited to announce topline performance data for the month of June, which featured over $1.3 million in sales, representing over 40% sequential monthly revenue growth. This performance demonstrates a dramatic acceleration in month-over-month growth.“June set new records for the Company, with a massive acceleration in the pace of growth, which is so far continuing in July,” stated Simon Yu, CEO of Cannabis Strategic Ventures. “We have successfully repositioned ourselves in the ecosystem of the California cannabis marketplace, moving up the ladder and widening our distribution footprint. We will continue to focus on ramping production capacity and steadily driving gains in quality, efficiency, and volume. That has been our focus all year. Besides dramatic expansion in sales volume by weight, we have also been rewarded by the market with steady gains in pricing. That represents the ultimate positive reinforcement.”Helping to drive performance in June, management notes that the Company’s move in April to more than double its production capacity paid off in the form of expanded production last month as harvest size increased sharply. Prior to the expansion in harvest size, the Company had been consistently selling out of its entire inventory on a weekly basis.To enable continued robust sales growth in the second half of the year and in 2021, and as noted in the Company’s release dated June 17, Cannabis Strategic Ventures is in discussions aimed toward obtaining additional square footage up to 300,000 square feet of greenhouse capacity for cannabis cultivation, which would more than double the Company’s current production capacity.Cannabis Strategic Ventures has a growing social media presence. Follow us on:
Twitter: @NUGS_stock
Instagram: @nugs_farm
About Cannabis Strategic Ventures
Cannabis Strategic Ventures Inc. (OTC: NUGS) is one of the largest publicly traded marijuana cultivators in the United States. The Company is Los Angeles-based and incubates, develops and partners with category leaders within the cannabis and ancillary sectors. The Firm’s NUGS brand experience provides operational and financial strategic partnerships and a range of essential services to emerging and existing Cannabis consumer brands.
For more information, visit
FORWARD-LOOKING STATEMENTS: This release contains „forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements also may be included in other publicly available documents issued by the Company and in oral statements made by our officers and representatives from time to time. These forward-looking statements are intended to provide management’s current expectations or plans for our future operating and financial performance, based on assumptions currently believed to be valid. They can be identified by the use of words such as „anticipate,” „intend,” „plan,” „goal,” „seek,” „believe,” „project,” „estimate,” „expect,” „strategy,” „future,” „likely,” „may,” „should,” „would,” „could,” „will” and other words of similar meaning in connection with a discussion of future operating or financial performance.
Examples of forward-looking statements include, among others, statements relating to future sales, earnings, cash flows, results of operations, uses of cash and other measures of financial performance.Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and other factors that may cause the Company’s actual results and financial condition to differ materially from those expressed or implied in the forward-looking statements. Such risks, uncertainties and other factors include, among others such as, but not limited to economic conditions, changes in the laws or regulations, demand for products and services of the company, the effects of competition and other factors that could cause actual results to differ materially from those projected or represented in the forward-looking statements. Any forward-looking information provided in this release should be considered with these factors in mind. We assume no obligation to update any forward-looking statements contained in this report.Corporate Contact:
Investor Relations Contact:
Tiger Global Management

Corporate Communications:
InvestorBrandNetwork (IBN)
Los Angeles, California
310.299.1717 Office

CBD Edibles vs THC Edibles: Is There Any Difference? – SPONSORED CONTENT – Riverfront Times

click to enlarge 04_-_thursday_image_-_buy_cbd_gummies.png

This article was originally published on BuyCBDGummies. To view the original article, click here.

CBD Edibles Vs. THC Edibles: Is There Any Difference?
CBD and THC are two terms that are creating a huge uproar in the healthcare industry. You might be already familiar with these names, as they are two prominent compounds present in the cannabis plant that is well known across the world. As you can imagine, the common source of derivation gave them some similarities, however, they also carry a wide range of differences too.

Both CBD and THC are found to exhibit a variety of medicinal properties, hence they are now commonly used in different medicines and healthcare products. One of those products, which gained huge popularity over a short span of time is the edibles. You can get both CBD and THC edibles in the market. They have different properties, hence, it is important to know about them for selecting the right product for you. So we include a comparison between CBD edibles and THC edibles so that it will be easy for you to find out which is the right product for you.

CBD Edibles
As the name indicates, these are food items that contain CBD. A lot of CBD edibles are available in the market including cookies, chocolates, CBD gummies, etc. The benefits of CBD edibles are similar to the benefits provided by any other CBD product. A lot of people use CBD edibles for getting a wide range of health benefits provided by this compound.

Why CBD Edibles Are Favored By People?
CBD is a non-psychoactive element, hence, it does not create any intoxicating effects. Therefore, you will be able to experience the pharmaceutical benefits provided by the cannabis plant without getting high. The commonly recognized benefits of CBD edibles include its effectiveness in relieving pain, reducing anxiety and depression, promoting better sleep, etc. Many people consume it on a daily basis as a health supplement. Hence, this compound has improved its status from an illegal compound to a product that is widely used by people across different parts of the world.

THC Edibles
Like CBD, THC also has different medicinal properties. However, it can cause intoxicating effects in people, hence, it is considered illegal. But products that contain only 0.3% of THC are allowed, as it will not create a “high” feeling as the amount is very low.

The main problem with THC edibles is that it may contain higher concentrations of THC than the permitted levels. Hence, it can have mind-altering effects. Also, if you use them for a long time, it can result in addiction too. So you have to be very careful when buying THC edibles and make sure that the level of THC present in the product is within the permitted level.

CBD and Vaping: What are the Risks and Advantages? – The Cannabis Exchange

According to Action on Smoking Health, more than 3.5 million people use e-cigarettes (vapes) in the UK today – almost five times more than back in 2012. Vaping has become extremely popular as it’s relatively cheap compared to smoking cigarettes and is widely considered to be a less harmful option. In the same time, CBD consumption has also been on the increase, naturally leading to a crossover of the two products. However, we must be aware of the risks that may come with vaping CBD.

You might have heard a thing or two about the reported benefits of vaping. The e-liquid contains a mix of nicotine, water, solvents, and flavours, and its lack of tobacco is usually considered to be the biggest selling point of the products. It has often been reported that vaping helps to quit smoking cigarettes and to relax. On the other hand, it must be underlined that this is yet to be proven.

So, what is Vaping?

E-cigarettes are free from tobacco, but this doesn’t mean that they don’t contain a lot of harmful chemicals. While traditional cigarettes can harm the smoker in the long run and could lead to severe, painful health issues, such as lung cancer, emphysema, and heart attacks, research has found that vaping may also lead to serious health problems.

Usually, these issues are the results of consuming, cheaply-made e-liquids that contain more toxic chemicals. In addition, according to the National Institute of Health (NIH), vaping has been found to potentially cause cell mutation, leading to an increased risk of lung cancer in mice.

The Recent Vaping Illness Outbreak

Vape products made headlines around the world last year when a large number of users experienced lung illnesses. The majority of these cases were reported in the USA. A number of people suffered from life-changing illnesses, and some even died from vape-related complications. It is widely accepted that the complications were the result of cheap vapes containing unapproved ingredients. Some sources believe that unregulated products containing cannabis derivatives may also have played a role in the outbreak.

CBD and Vaping

CBD can be consumed in a number of ways, and vaping is one of the most popular methods. However, both the risks and benefits of CBD vaping should be considered. To inhale the product smokers use CBD cartridges which are slim disposable e-cig tanks filled with ‘e-juice’.

Some might be surprised here to learn that CBD made directly for consuming via a vaporiser doesn’t actually contain oil. CBD vape products are made using food ingredients and are completely different from CBD oils. If you are thinking about vaping CBD, you should always make sure that the product was designed for this purpose. Vaping CBD oils, as opposed to e-liquids, can cause health complications associated with the lungs.

But is it for me?

Despite the aforementioned horror stories, we do know that there are a number of potential benefits of vaping CBD.

First and foremost, it is absorbed rather quickly, thanks to the high absorption rate in the lungs. Vaping is the most efficient way to take CBD and effects last around 1 to 3 hours. Many users report that it eases anxiety and stress as well as offering pain relief.

You must be careful, though, as if the juice contains anything other than “Propylene Glycol (PG), Vegetable Glycerin (VG), CBD extract, terpenes, and cannabinoids, then it’s most likely unsuitable for inhalation.

The label must be clear, and it must contain words like “vaping”, “vape juice”, “e-liquid” or “e-juice”. In a highly unregulated market, it is crucial that CBD vape products are always thoroughly inspected and consumed with caution.

No Newer Articles

Cannabis Solutions Providers Usher In New Era Of Mainstream Marketing – Forbes

Nice head shot of subtly smiling Chad Bronstein

Chad Bronstein

Photo Courtesy: Chad Bronstein

For decades, mainstream and cannabis companies have largely operated within their distinct lanes. Federal and regional regulations created seemingly impenetrable boundaries for both sectors to work together to reach new audiences, but as the national legalization movement continues to accelerate and an increasing number of consumers embrace legal cannabis products, the lucrative potential of cannabis consumer data can no longer be overlooked by mainstream companies.

However, these established industries can face frustrating obstacles in their attempts to access valuable consumer data and are often using outdated or wildly inaccurate information to make critical marketing decisions. Cannabis data and solutions companies including Fyllo and New Frontier Data have recognized the resonating demand for comprehensive industry data from mainstream companies and have developed pioneering technologies that will ultimately bridge these glaring and costly data gaps.

This week, Fyllo launched Cannabis Derived Audiences, a platform within its Data Marketplace that provides cannabis consumer profiles to mainstream marketers for programmatic media buying and audience targeting. The company has partnered with audience technology platform Eyeota to bring its trove of unique datasets to mainstream companies eager to engage with new consumer audiences.

Fyllo’s over 11 million consumer data profiles, which accounts for roughly half of the entire legal market, can be leveraged by mainstream CPG, fitness and wellness, retail and hospitality brands to fine tune their audience outreach and marketing strategies. The company’s industry-specific audiences, such as edible, sativa or recreational purchasers, can be overlaid on traditional consumer groups, including hiking enthusiasts, fast food lovers, or wine enthusiasts, to create a new series of segments that not only resonate with traditional audiences but also target the modern cannabis purchaser persona.

Fyllo Founder and CEO Chad Bronstein believes that this service can open the floodgates to a new wave of marketing synergies and potentially upend established marketing norms.

“It’s rare that an entirely new data set comes to market that can drive innovation. Our initial partnership with Eyeota allows us to bring Cannabis Derived Audiences to market at an enterprise level, with the data quality, compliance and privacy rigor the ad tech industry expects. We look forward to enabling access of an entirely new data set so brands spanning key sectors can tap into an entirely new set of data attributes to drive efficiencies and enhance campaigns.”

Similarly, New Frontier Data introduced NXTeck, a data solutions platform that connects mainstream advertisers with data insights from over 100 million CBD consumers nationwide. Through this service, brand advertisers can use these CBD data points, which provide valuable insights into consumer preferences, demographics and interests to efficiently discover, segment and target potential new customers that align with the brand’s lifestyle or messaging.

For example, fitness or athleisure companies aiming to reach new and receptive audiences can tap into NXTeck or Cannabis Derived Audiences datasets and strategically target consumers who are purchasing CBD edibles or recovery topical products. Brands that utilize these new data tools will have the ability to accurately target key audiences and gain a competitive advantage within their own saturated markets.

The past few months have undoubtedly been a watershed moment for legal cannabis. The industry’s coveted essential status in 33 states in the midst of a global pandemic has allowed it to generate unprecedented levels of social and political acceptance. Studies estimate that the number of cannabis consumers in the U.S. will reach 46.6 million people by 2025, which means that companies like Fyllo and New Frontier Data are currently sitting on a gold mine of insights that could potentially redefine how marketers develop and execute future campaigns. These recent technological advancements not only exemplify the impressive maturity of the overall industry, but also speak to the extraordinary economic value of an industry that is now on the cusp of entering the mainstream.

Loans for Legal Cannabis Firms: Chicago Lender Plans to Raise Capital Through Coin Sale – CoinDesk

Chicago based firm Ceres wants to build a “seed to sale” transaction network for cannabis on the blockchain using its dollar-backed stablecoin – if the digital security is approved for sale by the U.S. Securities and Exchange Commission (SEC). 

Launched in 2017 by West Point graduates and former U.S. soldiers Greg Anderson and Charlie Uchill, Ceres recently filed paperwork with the SEC to conduct a Reg. A sale, seeking permission to sell both a token and a coin. The token would represent an equity holding in the company, but the firm plans to use the coins as an actual transaction tool in its payments network. According to the application, the firm plans to sell up to $30 million worth of its tokens and $20 million in Ceres coins. 

In addition to its plans to build a payments network, Ceres also markets itself as a lender for legal cannabis businesses, though Urchill – the company’s chief operating officer – said Ceres has yet to disburse any loans, and is counting on the digital securities sale to raise capital. 

The firm’s SEC paperwork also notes that token holders, as a group, shall be entitled to receive 80% of the firm’s net revenues from its loan business and 20% of net revenues from the blockchain-enabled payments system. 

“We have been working with the SEC for 18 months,” Urchill said, referring to the process of getting approval to sell the firm’s digital securities. “I tell investors that we lost every battle with the SEC to win the war to have SEC approval.” 

As for the firm’s proposed transaction network for the legal cannabis industry, Ceres’ filing claims that its blockchain based network would improve transparency and aid compliance with regulations against money laundering and fraud. But the success of the blockchain network would also largely depend on producers, investors and consumers warming up to its stablecoin. 

Urchill said the only time actual dollars would have to be used under the firm’s model would be when consumers paid Ceres to get its coin, and when loans were given out to producers. All of the other transactions among consumers, dispensaries, and producers would involve the firm’s coin. 

According to the firm’s SEC filing, upon approval Ceres anticipates that it will target its marketing and sales efforts primarily in the states of Illinois and Washington where the firm “has identified certain strategic business opportunities,” related to its payment network, coins and tokens. Washington was the first U.S. state to legalize recreational marijiuanan in 2012, and Illinois legalized it this past January. 

The firm’s application also notes that there is currently no trading platform available to sell the company’s tokens, and that it remains uncertain whether one will be available in the future. As an alternative, the firm suggests that it might conduct the sale on its own website. 

Awaiting SEC approval for its securities, Ceres hopes to capitalize on the growing legal marijunan industry in the US, the size of which was estimated to be $13.6 billion in 2019, according to a report by Investopedia.


The leader in blockchain news, CoinDesk is a media outlet that strives for the highest journalistic standards and abides by a strict set of editorial policies. CoinDesk is an independent operating subsidiary of Digital Currency Group, which invests in cryptocurrencies and blockchain startups.

Global Marijuana Vaporizer Industry Analysis by Manufacturers, Production Capacity, Market Share, Price, Mergers & Acquisitions – Internet Shots

The global Marijuana Vaporizer market is valued at US$ xx million in 2020 is expected to reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2021-2026.

Access more details about this report at:

(This is our latest offering and this report also analyzes the impact of COVID-19 on Marijuana Vaporizer market and updated by the current situation, especially the forecast)

Global Marijuana Vaporizer Market: Drivers and Restrains:

The research report has incorporated the analysis of different factors that augment the market’s growth. It constitutes trends, restraints, and drivers that transform the market in either a positive or negative manner. This section also provides the scope of different segments and applications that can potentially influence the market in the future. The detailed information is based on current trends and historic milestones. This section also provides an analysis of the volume of production about the global market and also about each type from 2015 to 2026. This section mentions the volume of production by region from 2015 to 2026. Pricing analysis is included in the report according to each type from the year 2015 to 2026, manufacturer from 2015 to 2020, region from 2015 to 2020, and global price from 2015 to 2026.

A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing market. Additionally, insights into market expert’s opinions have been taken to understand the market better.

The major players in the market include Aphria, Etain, The Nug, Grizzly Guru, Innokin, FGB Natural Products, Chart Industries, etc.

Purchase this exclusive research report at:

Global Marijuana Vaporizer Market: Regional Analysis

The report offers in-depth assessment of the growth and other aspects of the Marijuana Vaporizer market in important regions, including the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc. Key regions covered in the report are North America, Europe, Asia-Pacific and Latin America.

The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, production, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2026. These analyses will help the reader to understand the potential worth of investment in a particular region.

Global Marijuana Vaporizer Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and production by manufacturers during the forecast period of 2015 to 2019.

Inquire for more details / sample / customization about this report at: